Overall response by overall study response criteria
| Response . | Overall study response criteria . | |||
|---|---|---|---|---|
| All patients (N = 25), % (95% CI) . | Patients in expansion phase (N = 15), % (95% CI) . | |||
| Best response | ||||
| CR | n = 2 | 8 (1-26) | n = 1 | 7 (0-32) |
| PR | n = 13 | 52 (31-72) | n = 7 | 47 (21-73) |
| MR | n = 3 | 12 (3-31) | n = 2 | 13 (2-40) |
| NC | n = 2 | 8 (1-26) | n = 2 | 13 (2-40) |
| PD | n = 1 | 4 (0-20) | n = 1 | 7 (0-32) |
| Not evaluable* | n = 4 | 16 (5-36) | n = 2 | 13 (2-40) |
| Overall response (CR + PR + MR) | n = 18 | 72 (51-88) | n = 10 | 60 (38-88) |
| Response . | Overall study response criteria . | |||
|---|---|---|---|---|
| All patients (N = 25), % (95% CI) . | Patients in expansion phase (N = 15), % (95% CI) . | |||
| Best response | ||||
| CR | n = 2 | 8 (1-26) | n = 1 | 7 (0-32) |
| PR | n = 13 | 52 (31-72) | n = 7 | 47 (21-73) |
| MR | n = 3 | 12 (3-31) | n = 2 | 13 (2-40) |
| NC | n = 2 | 8 (1-26) | n = 2 | 13 (2-40) |
| PD | n = 1 | 4 (0-20) | n = 1 | 7 (0-32) |
| Not evaluable* | n = 4 | 16 (5-36) | n = 2 | 13 (2-40) |
| Overall response (CR + PR + MR) | n = 18 | 72 (51-88) | n = 10 | 60 (38-88) |
Patients came off study prior to the first scheduled assessment prior to cycle 3.
PD indicates progressive disease.